Study of AG10 in Amyloid Cardiomyopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 27, 2018

Primary Completion Date

October 5, 2018

Study Completion Date

October 5, 2018

Conditions
Familial ATTR-CM (ATTRm-CM, or FAC)Wild-type ATTR-CM (ATTRwt-CM)
Interventions
DRUG

AG10

TTR stabilizer

DRUG

Placebo Oral Tablet

Nonactive control

Trial Locations (13)

10032

Columbia University, New York

29424

Medical University of South Carolina, Charleston

44195

Cleveland Clinic, Cleveland

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

84132

University of Utah, Salt Lake City

90211

Cedars-Sinai Medical Center, Beverly Hills

94143

University of California San Francisco, San Francisco

94304

Stanford University, Palo Alto

97239

Oregon Health & Science University, Portland

06520

Yale University, New Haven

02115

Brigham and Women's Hospital, Boston

02127

Boston University, Boston

All Listed Sponsors
lead

Eidos Therapeutics, a BridgeBio company

INDUSTRY

NCT03458130 - Study of AG10 in Amyloid Cardiomyopathy | Biotech Hunter | Biotech Hunter